Based on technology originating at the Bascom Palmer Eye Institute at the University of Miami, the EyeGate® II Delivery System has been used in over 1,700 clinical treatments to-date, including more than 1,000 treatments delivering our lead therapeutic candidate, EGP-437.
The system utilizes a low-level electrical current to deliver a specified amount of drug for each treatment. Powered by iontophoresis, this non-invasive delivery method mitigates many of the non-compliance and other risks of topical administration (drops) as well as the safety issues and challenges of invasive treatments (injection).
In addition to significant therapeutic, safety and convenience advantages for patients, the EyeGate® II Delivery System can substantively benefit physician practices. Intraocular injections are time and labor intensive, and should be administered by an experienced ophthalmologist. As such, injectable therapies limit the number of patients that can be treated and strain the resources of the practice.
Using our EyeGate® II Delivery System, treatments can be administered by a wider group of eye care practitioners. In-office preparation is simple and efficient, and can be completed by nursing or other office staff. Dosing takes approximately three minutes per eye, while total treatment time including preparation is roughly seven minutes per eye.
The EyeGate® II Delivery System consists of:
- An applicator kit that includes:
- An applicator used to deliver the drug product to the eye;
- A syringe and adapter transfer system for transferring the drug product from a vial to the applicator; and
- A return electrode to complete the continuous current circuit;
- A vial containing the drug product; and
- A generator that provides a constant current to the electrode of the applicator.